The in vivo activity of human immunoglobulin M monoclonal antibody IN-2A8, which is specific for flagellum type b ofPseudomonas aeruginosa, was evaluated in comparison to anti-O antigen (serotype B) MAb KO-2F2 and in combination with antibiotics. IN-2A8 showed stronger activity than KO-2F2 against subcutaneous infection in burned mice, while it was much less active against intraperitoneal infection in normal mice. In a burn infection model, IN-2A8 inhibited the increase of bacteria in skin lesions weakly and that in blood significantly, suggesting that it strongly suppressed bacterial spread to blood. The activity of IN-2A8 in combination with 10 antipseudomonal antibiotics against intraperitoneal infection was examined. Clear additive effect was observed with a combination of either carbapenem or aminoglycoside antibiotics in terms of mouse survival. The administration of an antibiotic, imipenem-cilastatin, simultaneously with or before that of IN-2A8 gave a combined effect, but the reverse order did not. The combination of IN-2A8 with imipenem-cilastatin decreased numbers of viable bacteria in the peritoneal cavity and blood and kept them low for a longer time than did either treatment alone. These results suggest that an antiflageUar monoclonal antibody would be effective against systemic infection in combination with some kinds of antibiotics.
Pseudomonas aeruginosa is recognized as a serious opportunistic pathogen in compromised hosts. Antibiotic therapy against P. aeruginosa infection has met with only limited success, because the causative strains have become increasingly resistant (4, 13, 20) . Meanwhile, the potential of active or passive immunization to enhance protective activity against P. aeruginosa infection has been suggested in several reports (1, 6, 15, 19, 21, 23, 30) . The lipopolysaccharide (8) and flagella (10, 16) of P. aeruginosa have been shown to be associated with its virulence and have been studied for their effectiveness as protective antigens (2, 6, 7, 11, 14, 23) . Monoclonal antibodies (MAbs) specific for 0 polysaccharides of lipopolysaccharide have been reported to be highly protective (22, 24, 26, 28) . However, these antibodies have narrow efficacy spectra, because there are 13 to 17 serotypes of lipopolysaccharide and each MAb is reactive only to the strains of a specific serotype (26) .
On the other hand, flagella of P. aeruginosa are known to be classified as only two serotypes, designated a and b (3) . Passive protection with antiflagellar antisera (9) or MAbs (25) against P. aeruginosa in mice challenged subcutaneously (s.c.) after they were burned has been demonstrated, although no studies compared their activities with those of other types of MAbs in one experiment. This model is suggested to be that of a local infection resulting in systemic sepsis, because the appearance of the bacteria in the blood is the result of rapid growth in the skin lesion. 
MATERIALS AND METHODS
MAbs. The production of human IgM MAbs IN-2A8 and KO-2F2 against P. aeruginosa was described by Ochi et al. (18) . IN-2A8 is specifically reactive to b-type flagella, and KO-2F2 is specific for the 0 antigen of Homma's serotype B strains. They were chromatographically purified and used for the experiments.
Bacterial strains. P. aeruginosa SP10052 was a clinical isolate of serotype B and was reactive to the two MAbs described. The serotype of the bacterium was determined by a serotype grouping kit Mei assay (Meiji Seika Co., Tokyo, Japan) after the bacterium was cultured on heart infusion agar (Nissui Pharmaceuticals, Tokyo, Japan) at 37°C for 18 h. It was shown to produce exotoxin A, elastase, and protease. It was grown as described above and kept frozen at -80°C in water-40% glycerol.
Antibiotics. Antibiotics used were imipenem-cilastatin (IPM-CS) (Tienam; Banyu Pharmaceutical, Tokyo, Japan); SM-7338 (Meropenem), synthesized in the Research Laboratory of Sumitomo Pharmaceuticals, Osaka, Japan; tobramycin (Shionogi Pharmaceuticals, Osaka, Japan); gentamicin (Essex Japan, Osaka, Japan); ceftazidime (Tanabe Pharmaceuticals, Osaka, Japan); cefsulodin (Takeda Chemical, Osaka, Japan); cefpiramide (Sumitomo Pharmaceuticals, Osaka, Japan); aztreonam (Eisai Pharmaceutical, Tokyo, Japan); carmonam (Takeda Chemical); and piperacillin (Toyama Chemical, Tokyo, Japan).
Protection experiments with mice. Four-week-old male ICR mice (Japan SLC Inc., Shizuoka, Japan) (body weight, 22 to 24 g) were used in the following experimental infection models. P. aeruginosa SP10052 (serotype B) was cultured on heart infusion agar at 37°C for 18 h.
(i) Burn infection model. Burned mice were prepared according to the method of Stieritz and Holder (27) , with some modification. After anesthesia, an 8-cm2 burn was created on the shaved backs of mice by pressing an ethanol flame on a glass filter for 10 s. Immediately after burning, 0.3 ml of saline was injected i.p. for fluid replacement, and the bacterial suspension in 0.2 ml of saline was inoculated s.c. at the burned site. One hour later, 0.2 ml of MAb with or without an antibiotic in phosphate-buffered saline (PBS) was intravenously injected. The survival of animals was observed for 7 days. The 50% lethal dose (LD50) of challenged bacteria was calculated by probit analysis. The significant difference was indicated by nonoverlapping 95% confidence intervals.
(ii) Systemic-infection model. Bacterial suspension was serially diluted in saline and mixed with bacteriological mucin (Difco Laboratories, Detroit, Mich.). Two hundred microliters of the bacterial suspension containing 5% mucin was injected into the peritoneums of the mice. One hour later, 0.2 ml of MAb with or without an antibiotic in PBS was injected i.p. The negative-control group received neither MAb nor an antibiotic. The observation and the analysis of the results were done in a manner similar to that for the burn infection model.
Bacterial counts in blood and tissues. At time intervals after the inoculation of P. aeruginosa, animals were sacrificed. Blood was collected by cardiac puncture, and 1 ml of peritoneal fluid was collected after the puncture was washed with 2 ml of saline containing 0.1% bovine serum albumin. In the case of burned mice, full-thickness samples of burned skin were also removed, weighed, and homogenized in sterile saline with sea sand; the homogenized samples were then centrifuged at 200 x g for 1 min to remove debris, and the supernatant was collected. Numbers of viable bacteria in blood (CFU per milliliter), in the peritoneal cavity (CFU per peritoneal cavity), and in skin (CFU per gram of tissue) were counted by using 10-fold serial dilution plates in duplicate on heart infusion agar. The results were expressed as means ± standard deviations or as each value for four to five animals sacrificed at each time.
RESULTS
Protection against experimental infection in mice. We compared the protective activity of antiflagellar human IgM MAb IN-2A8 with that of another type of MAb, KO-2F2, which was directed against the 0 polysaccharide of P. aeruginosa serotype B strains, by using a clinical isolate, SP10052, as the challenge bacterium in two experimental infection models with mice.
In cases of s.c. infection after burn, the LD50 for the groups treated with 1 ,ug of IN-2A8 or KO-2F2 per mouse was about 2,300 or 75 times higher, respectively, than that for the untreated group (Table 1) . The protective activity of IN-2A8 was significantly higher than that of KO-2F2. The high protective activity of IN-2A8 against burn infection shown in the previous study (18) (Fig. 2) . The antibiotics were two aminoglycosides and eight P-lactams, classified into carbapenems, cephalosporins, monobactams, and penicillins. The results of four experiments, which confirmed the reproducibility, were demonstrated in Fig. 2 in terms of survival rates of infected mice. Among the antibiotics tested, two carbapenems (IPM-CS and SM-7338) and an aminoglycoside (tobramycin) showed the most clear combined effect against not only low but also high challenge doses of bacteria. The effect of cephalosporins was moderate, and that of a penicillin was rather poor (Fig. 2) .
We 
LD50, indicating a significant additive effect between IN-2A8
and IPM-CS ( Table 2 ). As to the treatment schedule with both agents, we observed that it was necessary to administer IPM-CS simultaneously with or before the MAb to maintain the combined effects. The efficacy was not changed if the order of administration was the same, even if IN-2A8 was delayed within 6 h following IPM-CS (Fig. 3) .
Bacterial count after i.p. infection. In order to study the mechanism of the combined effects of IN-2A8 and IPM-CS, we counted the bacterial numbers in the peritoneum and in blood after i.p. infection (Fig. 4) and recorded the survival rates of mice simultaneously (Fig. 5 ). Mice were inoculated with 1.1 x 107 CFU ofP. aeruginosa SP10052, against which MAb IN-2A8 alone was not effective, even at a dose of 10 ,g per mouse (data not shown). One hour after infection, mice were simultaneously treated with both 1 pLg of IN-2A8 and 100 ,ug of IPM-CS per mouse. In control mice, rapid proliferation of bacteria was observed, reaching 109 CFU in the peritoneal cavity and 106 CFU/ml in blood (Fig. 4) , which resulted in the deaths of the mice 7 h after infection (Fig. 5) . MAb IN-2A8 alone did not inhibit bacterial growth either in the peritoneal cavity or in blood. IPM-CS alone reduced the number of bacteria in the peritoneal cavity for 7 h after the infection, but a gradual increase was shown thereafter. Mice treated with IPM-CS alone began to die 15 h after infection. Combination therapy with IN-2A8 and IPM-CS reduced the numbers of bacteria both in the peritoneal cavity and in blood as well as did IPM-CS alone within 7 h after infection. The regrowth of bacteria after that time in the peritoneal cavity was partially suppressed by the combined administration of IN-2A8 with IPM-CS in contrast to IPM-CS alone (Fig. 4) . The bacterial cell number in blood was suppressed in almost all mice treated with both agents, at least for 18 h after infection. The change of bacterial numbers in the peritoneal cavity and blood correlated well with the duration of survival and the final survival rates of the mice. The final survival rates for groups of untreated mice, mice treated with MAb IN-2A8 alone, mice treated with IPM-CS alone, and mice treated with MAb IN-2A8 combined with IPM-CS were 0, 0, 10, and 55%, respectively (Fig. 5) . DISCUSSION Flagella of P. aeruginosa are said to be involved in the pathogenesis and virulence of this bacterium in infection (10, 16) . Some studies have demonstrated the protective activity of antiflagellar antisera or MABs against s.c. infection in burned mice (9, 25 (18) .
Here we demonstrated that the antiflagellar MAb IN-2A8 had much stronger protective activity than 0 antigen-specific MAb KO-2F2 against the local infection model described above (Table 1) , in spite of the weaker opsonophagocytic activity in vitro (18) . In contrast, IN-2A8 showed only weak protective activity against i.p. infection in normal mice, while KO-2F2 was strongly protective (Table 1 ). This infection system was considered to be a model of acute systemic infection (sepsis), as rapid growth of infected bacteria was observed in both the peritoneum and blood, resulting in the death of mice (Fig. 4) .
In a burn infection model, the almost complete inhibition of bacterial dissemination into the blood by IN-2A8 was observed and was accompanied by the weak suppression of the growth in the skin lesion (Fig. 1) . This phenomenon correlated well to the survival of mice as shown in the great increase of the LD50 (Table 1) , and this result itself suggested that this system is essentially the model of local infection.
The result also seemed to be in part the result of weak opsonophagocytic activity of IN-2A8, as shown in the former study (18) with human neutrophils. Similar activity was also demonstrated with mouse peritoneal exudate cells (data not shown). The weak activity of antiflagellar MAb and the strong activity of anti-O antigen MAb against systemic infection also seemed to be in good correlation with their in vitro opsonophagocytic activities. These in vivo results, in conjunction with the in vitro activities of IN-2A8 (18), strongly suggest that flagella of P. aeruginosa play an important role for its pathogenesis, especially in local infection, and that the inhibition of bacterial motility by IN-2A8 is a key factor for the protection against it while opsonophagocytosis is an essential protective mechanism against systemic infection.
Moderate to strong enhancement of the protective activity of IN-2A8 by combination of the MAb with antibiotics was VOL. 36, 1992 observed with 8 of 10 reagents tested (Fig. 2) in a systemicinfection model. Carbapenems and aminoglycoside antibiotics seemed to be most effective, followed by cephalosporins. What is the mechanism for the combined effects of MAb IN-2A8 and antibiotics, and what is the reason for the differences of the effects among the antibiotics? There might be some answers to this question. First, the antibiotic might alter the bacterial cell wall so that the MAb would be able to kill bacteria more effectively. It is well known that a subbactericidal concentration of IPM causes bulge formation of P. aeruginosa, which then becomes more sensitive to a low concentration of a detergent (12) . Similarly, the bacteria treated with IPM might be more susceptible to complement and/or MAb IN-2A8 in some unknown way. Morphological investigation of bacteria after treatment with IPM and IN-2A8 is now under way. The second possible explanation is that the antibiotic might enhance the activity of phagocytes so that the organisms would be more efficiently removed or killed in the presence of weak opsonic activity of MAb IN-2A8. In fact, it is known that IPM enhances the opsonophagocytic activity of mouse phagocytes (17) . Such enhancement of phagocytosis, however, was not observed in our preliminary in vitro experiments. The third possible explanation for the above question is that the decrease of the total bacterial number in a body by the antibiotic administered would benefit the efficient removal of living cells by MAb. In fact, carbapenem and aminoglycoside antibiotics were shown to have potent bactericidal activities (29) and to decrease the number of viable bacteria in the peritoneal cavity to a great extent.
As to the schedule of combination therapy, it was shown to be necessary to administer IPM-CS simultaneously with or earlier than MAb IN-2A8 after the infection (Fig. 3) . When the mice were treated with the combination in this order, the efficacy was not changed even if the administration of MAb was delayed to 6 h after that of the antibiotic. This result might mean that the effect of IPM-CS lasted for 6 h and might be associated with so-called "post-antibiotic effect" (5), the nature of which is not yet understood.
Here we demonstrated for the first time that antiflagellar MAb was protective against a systemic i.p. infection model with normal mice as well as against a local infection model with burned mice, when the MAb was used in combination with either carbapenem or aminoglycoside antibiotics. As combination therapy of immunoglobulins with antibiotics usually has been conducted with patients with severe infection, antiflagellar MAb IN-2A8 might be effectively used in place of immunoglobulins in the regimen of antipseudomonal therapy.
